Merck has announced positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH). The study met its primary endpoint of reducing the risk of morbidity or mortality events compared to placebo.   Based on these results, an independent data monitoring committee recommended early termination of the study, and all participants will be offered access to WINREVAIR through an open-label extension study. Adverse even...